Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Tarun Gera Division of
Clinical Epidemiology, Department of Paediatrics, Maulana Azad Medical
College, New Delhi 110002, India Correspondence to: H P S
Sachdev, E-6/12, Vasant Vihar, New Dehli 110057, India hpssachdev{at}hotmail.com
| |
Abstract |
|---|
|
|
|---|
Objective:
To evaluate the effect of iron
supplementation on the incidence of infections in children.
Design:
Systematic review of randomised controlled trials.
Data sources:
28 randomised controlled trials (six
unpublished and 22 published) on 7892 children.
Interventions:
Oral or parenteral iron
supplementation or fortified formula milk or cereals.
Outcomes:
Incidence of all recorded infectious
illnesses, and individual illnesses, including respiratory tract
infection, diarrhoea, malaria, other infections, and prevalence of
positive smear results for malaria.
Results:
The pooled estimate (random effects model) of the incidence rate ratio (iron v placebo) was 1.02 (95%
confidence interval 0.96 to 1.08, P=0.54; P<0.0001 for
heterogeneity). The incidence rate difference (iron minus placebo) for
all recorded illnesses was 0.06 episodes/child year (
0.06 to 0.18, P=0.34; P<0.0001 for heterogeneity). However, there was an increase
in the risk of developing diarrhoea (incidence rate ratio 1.11, 1.01 to
1.23, P=0.04), but this would not have an overall important on public
health (incidence rate difference 0.05 episodes/child year,
0.03 to
0.13; P=0.21). The occurrence of other illnesses and positive results
on malaria smears (adjusted for positive smears at baseline) were not
significantly affected by iron administration. On meta-regression, the
statistical heterogeneity could not be explained by the variables studied.
Conclusion:
Iron supplementation has no apparent
harmful effect on the overall incidence of infectious illnesses in
children, though it slightly increases the risk of developing diarrhoea.
|
What is already known on this topic
Conflicting data exist regarding the possibility of an increase in the incidence of infections with iron supplementation, resulting in concern about the safety of this intervention What this study adds
Iron administration increases the risk of developing diarrhoea Fortification of foods may be the safest and most beneficial mode of supplementation in relation to infectious illnesses |
| |
Introduction |
|---|
|
|
|---|
Anaemia caused by iron deficiency is a major public health problem, affecting 46% of school children globally.1 Iron deficiency has adverse effects on psychomotor development.2 The reversible consequences in childhood have prompted recommendations for early intervention. The proposed interventions rely primarily on enhancing iron intake through supplementation or fortification of food. 3 4
Objective safety data from longitudinal studies of iron supplementation
are conflicting; trials have shown either beneficial effects,5 no effect,6 or an increase in
infectious illnesses.
7 8
Children, particularly infants
and those living in developing countries, are vulnerable to infectious
diseases. It is thus important to establish the safety of iron
supplementation in children on a public health scale. We conducted a
systematic review to determine the effect of iron supplementation on
infectious illnesses.
| |
Methods |
|---|
|
|
|---|
Inclusion criteria
To be included trials had to be randomised placebo controlled
trials; had to investigate iron supplementation through the oral or the
parenteral route or as formula milk or cereals fortified with iron ;
and evaluate one or more infectious illnesses as an outcome measure.
Data collection
We searched Medline, Cochrane controlled trials register, Embase,
IBIDS, and Healthstar. We also reviewed reference lists of identified
articles and hand searched reviews, bibliographies of books, and
abstracts and proceedings of international conferences or meetings.
Donor agencies, "experts," and authors of recent iron
supplementation trials were contacted to identify any additional or
ongoing trials. We included published and unpublished trials and
assessed quality using recommended criteria.
9 10
Statistical analysis
The presence of bias in the extracted data was evaluated by funnel
plots.11 We primarily report random effects estimates
because most of the pooled results obtained were statistically
heterogeneous (Q statistic). The data were recorded in the form of the
total number of episodes of illness and the person time exposed (in
child years).
Some studies had reported only on the prevalence of malaria parasitaemia confirmed from smears at the beginning and the end of the supplementation period. Pooled estimates of the odds ratio of positive smears at the end of the supplementation period were computed. We also performed a meta-regression to determine the pooled log odds ratio of developing malaria in the group with iron supplementation compared with the placebo group. The covariate in the meta-regression equation was the log odds ratio at the beginning of the trial to adjust for the baseline differences in the prevalence of malaria.
We carried out stratified analyses for quality of methods; case detection (active field based or passive facility based); specificity of case definition; route of iron administration (parenteral, oral supplement, or fortified food); duration of supplementation; type of illness (gastrointestinal, respiratory, malaria, non-diarrhoeal, or others); and baseline haemoglobin concentration in the supplemented group. The contribution of these variables to heterogeneity was also explored by meta-regression.
| |
Results |
|---|
|
|
|---|
We identified 47 randomised controlled trials that were potentially eligible. We finally included 28 studies (22 published, and six unpublished) in this systematic review (see also bmj.com).
Baseline characteristics of the studies
The detailed baseline characteristics of the included trials can
be found with the full version of this paper (see bmj.com). Thirteen
trials were in children aged <1 year, 10 studies included preschool
children (
5 years), and five trials included children aged >5
years. Eleven trials were from Africa, eight from Asia, five from the
Americas, two from Europe, and two from Australia and New Zealand. Most
of the studies used oral iron supplementation (20/28; 71%). Three
trials used parenteral administration, and five studies used iron
fortified foods.
The supplementation dose used could influence the degree to which illness was affected. As a crude generalisation, the fortified formulas had the lowest dosage and the parenteral route had the highest. The duration of supplementation and follow up for oral intake varied from 2 months to 30 months.
The specificity of the definition used for illness was variable. The methods of surveillance also varied: 15 were clinic based whereas 13 were field trials with active surveillance for cases. If iron supplementation has selective effects on mild rather than more severe episodes of illness then differences in methods of case detection may influence the observed effects of iron supplementation.
We found no evidence of bias (see bmj.com).
Pooled and stratified estimates
We collected data on 7892 children followed up for 5650 child
years
4027 children and 2802 child years in the iron supplemented
group and 3865 children and 2848 child years in the placebo group. The
pooled estimate of the incidence rate ratio (iron versus placebo) for
all the recorded morbidities was 1.02 (95% confidence interval 0.96 to
1.08; P=0.54; Q=78.3, P<0.0001, fig 1). From the public health
perspective the incidence rate difference is considered to be more
informative. The incidence rate difference for all the recorded
illnesses was 0.06 episodes per child year (
0.06 to 0.18, P=0.34).
|
Stratified analysis for the effect on individual infectious illnesses
showed that children in the iron supplementation group had an 11% (1%
to 23%) higher risk (incidence rate ratio) of developing diarrhoea
(P=0.04; Q= 30.24, P= 0.04, table). The effect on other individual illnesses was not significant. However, the incidence rate
difference (public health impact) for diarrhoea was 0.05 episodes per
child year (
0.03 to 0.13, P=0.21). Further stratification showed
that the significantly increased risk of diarrhoea associated with iron
supplementation was restricted to oral supplementation (nine studies;
incidence rate ratio 1.15, 1.01 to 1.32, P=0.04; incidence rate
difference 0.18 episodes per child year,
0.01 to 0.37; P=0.07).
Meta-regression showed that the route of iron administration (oral
versus other) was not significantly associated with incidence rate
ratio for diarrhoea.
|
From the available data we found no increased risk of severe illness associated with iron supplementation (analysis possible only for lower respiratory tract infection and dysentery).
Malarial parasitaemia
The pooled odds ratio for positive smear tests for malaria at the
end of the supplementation period was 1.43 (1.08 to 1.91, P=0.014;
Q=11.6, P=0.11, fig 2). Meta-regression analysis indicated that
this treatment effect was significantly associated with the baseline
positivity of smear tests (for a unit increase in log odds ratio of
baseline positivity, the treatment effect increased by 2.89; 1.37 to
6.10; P=0.005) but not iron supplementation (1.24; 0.98 to 1.57;
P=0.076).
|
Exploring heterogeneity
Stratified estimates indicated that iron supplementation did not
significantly increase the incidence of infections (incidence rate
ratio and incidence rate difference), irrespective of the quality of
methods, methods of surveillance, route of iron supplementation, duration of supplementation, geographic location of the study population, or the basal haemoglobin concentration of the iron supplemented group. Meta-regression analysis showed that the treatment effect was not significantly associated with any of these study characteristics (see bmj.com).
| |
Discussion |
|---|
|
|
|---|
The results from our analysis of these studies show that iron supplementation does not significantly increase the risk of overall infection. However, there was an increase in the risk of developing diarrhoea, but this would not have an important overall impact on public health. The occurrence of other illnesses and malarial parasitaemia (after adjustment for positive smear results at baseline) was not significantly affected by iron administration.
Strengths and limitations of analysis
Despite wide clinical and methodological heterogeneity in the various trials, the main inference remained stable for the
various sensitivity analyses that we performed (see bmj.com). An
important caveat is the lack of uniform definitions for the individual
clinical morbidities. Uniform definitions and active surveillance would
have provided greater weight to the conclusions. Furthermore, not all
the included trials were of high quality. We could not explain the
statistical heterogeneity by various study characteristics.
There are still some questions unanswered and some new issues raised. We could not analyse the effect of dose on the incidence of infections. However, the near absence of any important adverse effects, particularly diarrhoea, in children receiving fortified foods (compared with medicinal iron) raises the possibility of a dose related effect. Fortification with low doses of iron is closest to the physiological situation and could theoretically be considered the safest public health intervention. There is thus a case for concomitant evaluation of the possible beneficial effects of iron fortified foods on the haematological response and infections.
Meta-regression analysis suggested that the risk of acquiring infectious illnesses might be inversely associated with the baseline haemoglobin concentration (incidence rate ratio 0.95 (0.90 to 1.00), P=0.059). Interestingly, all the studies included in this stratified subset were from regions of the African continent where malaria is endemic. Some data suggest indirectly that iron deficiency in such regions decreases the susceptibility to disease related to malaria, HIV, and tuberculosis.12 The safety of iron supplementation in people with anaemia, particularly in regions where malaria is endemic, may be difficult to determine because of the ethical problem of withholding treatment in a control group.
| |
Acknowledgments |
|---|
We thank Sunil Sinha for facilitating access to Embase and two PhD dissertations. We also thank L Satyanaryana for help in conducting the meta-regression analysis. Part of this paper was presented as a poster at the International Nutritional Anaemia Consultative Group symposium 2001, held at Hanoi, Vietnam.
Contributors: See bmj.com
| |
Footnotes |
|---|
Editorial by Tomkins
Funding: None.
Competing interests: International Life Science Institute (ILSI) sponsored TG for travel to Hanoi, Vietnam for the purpose of attending the International Nutritional Anaemia Consultative Group symposium and presenting part of the analysis as a poster.
This is an abridged version; the
full version is on bmj.com
| |
References |
|---|
|
|
|---|
| 1. | United Nations Administrative Committee on Coordination Sub-Committee on Nutrition (ACC/SCN). Fourth report on the world nutrition situation. Geneva: ACC/SCN in collaboration with International Food Policy Research Institute, 2000. |
| 2. | Pollitt E. Iron deficiency anaemia and cognitive function. Ann Rev Nutr 1993; 13: 521-537[CrossRef][Web of Science][Medline]. |
| 3. |
American Academy of Pediatrics-Committee on Nutrition.
Nutritional needs of low-birth-weight infants.
Pediatrics
1985;
75:
976-986 |
| 4. | Hurrell RF. Preventing iron deficiency through food fortification. Nutr Rev 1997; 55: 210-222[Web of Science][Medline]. |
| 5. |
Chwang L, Soemantri AG, Polloitt E.
Iron supplementation and physical growth of rural Indonesian children.
Am J Clin Nutr
1988;
47:
496-501 |
| 6. | Idjradinata P, Watkins WE, Pollitt E. Adverse effect of iron supplementation on weight gain of iron replete young children. Lancet 1994; 343: 1252-1254[CrossRef][Web of Science][Medline]. |
| 7. | Smith AW, Hendrickse RG, Harrison C, Hayes RJ, Greenwood BM. The effects on malaria of treatment of iron deficiency anaemia with oral iron in Gambian children. Ann Trop Paediatr 1989; 9: 17-23[Web of Science][Medline]. |
| 8. | Murray MJ, Murray AB, Murray MB, Murray CJ. The adverse effect of iron repletion on the course of certain infections. BMJ 1978; ii: 1113-1115. |
| 9. | Juni P, Altman DG, Egger M. Assessing the quality of randomised controlled trials. In: Egger M, Smith GD, Altman DG, eds. Systematic reviews in health care: meta-analysis in context. London: BMJ Publishing, 2001:87-108. |
| 10. | Clarke M, Oxman AD, eds. Assessment of study quality. Cochrane reviewers handbook 4.1.1 [updated December 2000]. In: Cochrane Library. Issue 1. Oxford: Update Software, 2001. |
| 11. | Sterne JAC, Egger M, Smith GD. Investigating and dealing with publication and other biases. In: Egger M, Smith GD, Altman DG, eds. Systematic reviews in health care: meta-analysis in context. London: BMJ Publishing, 2001:189-208. |
| 12. | Oppenheimer SJ. Iron and its relation to immunity and infectious disease. J Nutr 2001; 131(suppl): 616-635S. |
(Accepted 28 June 2002)
Read all Rapid Responses